Numinus Wellness (NUMI) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
25 Jun, 2025Industry context and market opportunity
Global mental health issues are rising, with depression, anxiety, and substance abuse affecting millions and costing the global economy $1 trillion annually.
Current mental health systems are inadequate to address increasing rates of mental illness, addiction, and trauma.
The global mental health market is projected to grow from $380B in 2020 to $538B by 2030.
Business model and operations
Integrated model combines clinical therapy, psychedelic research, and practitioner training, serving clients, practitioners, and research organizations.
Transitioned out of Canadian clinical operations, focusing on U.S. clinics and research.
Wellness clinics generated ~80,000 appointments annually, addressing a wide range of mental health conditions.
Managed 15 clinical trials and provided 15,750 client appointments in Q3 FY24, a 3.2% increase year-over-year.
Financial performance
Q3 FY24 total revenue was $4.35M, with clinic network revenues at $3.36M and clinical research revenues at $824K.
Practitioner training revenue reached $168.8K in Q3 FY24, with over 1,650 learners enrolled from 18 countries.
Cost containment initiatives reduced overhead, with a near-term goal of positive EBITDA.
Cash and cash equivalents stood at $3.7M at the end of Q3 FY24.
Latest events from Numinus Wellness
- Q1 2025 saw 68% revenue growth, higher margins, and sharply reduced losses.NUMI
Q1 202523 Apr 2026 - Revenue surged 83.8% year-over-year, but net loss widened and cash reserves remain low.NUMI
Q2 202523 Apr 2026 - Revenue up 16.4% in Q4 2024, with improved margins and strategic U.S. asset sale.NUMI
Q4 202423 Apr 2026 - Revenue up 81.6% and gross margin turned positive as cost controls drive improved results.NUMI
Q3 202523 Apr 2026 - Cost cuts and MedBright AI deal drive U.S. shift and scalable, tech-enabled growth.NUMI
Q3 20243 Feb 2026 - Expanding U.S. operations, clinical trial growth, and licensing drive future profitability.NUMI
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - All AGM resolutions passed, with a strategic pivot to psychedelic medicine infrastructure.NUMI
AGM 202523 Nov 2025 - AI-driven expansion and practitioner training fuel growth in psychedelic mental health services.NUMI
Investor Presentation25 Jun 2025 - Expanding U.S. clinics, research, and training drive growth in the evolving mental health market.NUMI
Investor Presentation25 Jun 2025